Johnson & Johnson 2Q Revenues: $18.5 billion (+4%) 2Q Earnings: $4.0 billion (-12%) YTD Revenues: $36.0 billion (+2%) YTD Earnings: $8.5 billion (-4%) Comments: Worldwide Pharmaceutical sales were $8.7 billion for quarter, up 9% with domestic sales up 13% and international sales up 3%. Growth was driven by newer products including IMBRUVICA (up 92% to $295 million), XARELTO (up 26% to $594 million), INVOKANA/INVOKAMET (up 20% to $383 million), and ZYTIGA (up 10% to $601 millio...